INTRODUCE
联盟简介
FRAMEWORK
组织架构
COMPANY
联盟单位
ACTIVITY

联盟活动

Innovation Alliance on Tuberculosis Diagnosis and Treatmen...

2019-01-28

The Successful Opening of the Annual International Meeting...

2019-01-10

The 2018 National Symposium of Heads of TB Hospitals in Sh...

2019-01-10

The Successful Opening of the 4th International TB Forum a...

2019-01-09

The Successful Opening of the Fourth ‘China DR-TB Forum’

2018-12-04

The ‘Xiehe MDT Seminar’at Xian

2018-12-04

The Successful Opening of the National Academic Conference...

2018-12-04

The Successful Opening of the 1st Meeting of the Standing ...

2018-12-04

Establishment of a Long-term Platform-The Assembly of the ...

2018-04-17

Seminar on the Piloting Phase of the TB Patient Management...

2018-04-17

More
China Tuberculosis Clinical Trial Consortium(CTCTC)

中国结核病临床试验合作中心

China Tuberculosis Clinical Trial Consortium (CTCTC, hereafter,the consortium)serves as a nation-wide platform for collaboratively carrying out TB-related clinical trials. Its membership is consisted of numerous domestically and internationally renowned TB research teams and other relevant stakeholders who are committed to the clinical research and development of novel anti-TB agents, new preexposure vaccines and diagnostics. Founded in September 2013, the consortium adopts a governing system of the council, and led by the Capital Medical University’s Beijing Chest Hospital who occupies the council’s president-ship. A special office has been set up within the structure of the China Disease Control’s(CDC) TB Clinical and Prevention Center to undertake the daily operations of the consortium. A long-term collaboration has been established between the consortium and the United States National Institute of Health (NIH), who via its subsidiary the Family Health International 360 (FHI 360) has provided for the founding and development of the consortium with an all round technical support. In 2017, the consortium has formerly become one of the subsidiaries of the Innovation Alliance on Tuberculosis Diagnosis and Treatment (Beijing) (hereafter,IATB).

More
Remote Platform

远程平台

The National Tuberculosis Remote Platform of Professional Consultation and Training was unveiled on 23rd March 2012 in Beijing. Currently its coverage has extended to some 190 medical institutions across 31 provinces and regions in China. Utilizing remote communication technologies,the platform has undertaken a multitude of operations including medical consultation (multi-disciplinary consultation, consultation of complicated cases), medical training programs, professional exchanges and interactions, patient management, emergency assistance to name just a few. Thanks to its versatility, the platform has played a vital role in a number of major domestic emergencies, and grown into the largest remote professional platform in the field nation-wide.

More
TECHNOLOGY

技术平台

Property

Product

Conversion

Results

Research

Provisions

Publication

Data

LINK

友情链接

CONTACT US

联系我们

北京市通州区新华北路绿地中央广场二期写字楼1单元2012
chinaiatb@chinaiatb.org
010-69516740

北京结核病诊疗技术创新联盟微信公众号

结核帮公众号